person · Reporting owner

Frederick Wayne A.I.

Disclosed activity across 5 companies

Tapewire entity: 36733
SEC CIK: 0001802241

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HUMANA INCHUM · Entity 1429	Director	December 31, 2025	January 05, 2026
INSULET CORPPODD · Entity 3516	Director	May 20, 2026	May 21, 2026
Tempus AI, Inc.TEM · Entity 1545	Director	May 21, 2026	May 27, 2026
Workday, Inc.WDAY · Entity 1785	Director	June 16, 2026	June 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HUMANA INC

Report date December 31, 2025 · Filed January 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	3,174	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 766 · Balance 3,174 F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	73	Reported balance After 2025-12-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-31 · Grant · Acquired 35 · Balance 73 F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
Humana CommonSEC Table I · non-derivative	Direct	440	Reported balance Holding disclosure · report date 2025-12-31 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 440

Filing footnotes · ownership attribution and instrument terms

F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan.

F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).

INSULET CORP

Report date May 20, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,818	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 3,818 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. The Reporting Person has elected to defer settlement of these RSUs pursuant to the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the termination of the Reporting Person's service as a Director.

Filing footnotes · ownership attribution and instrument terms

F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. The Reporting Person has elected to defer settlement of these RSUs pursuant to the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the termination of the Reporting Person's service as a Director.

Tempus AI, Inc.

Report date May 21, 2026 · Filed May 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	30,749	Reported balance After 2026-05-21 transaction · row 1 1 source row Row 1 · 2026-05-21 · Grant · Acquired 5,913 · Balance 30,749 F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the Issuer's 2027 annual meeting of the stockholders (or the date immediately prior to such annual meeting if the Reporting Person's service as a director ends at such annual meeting) or (ii) on May 21, 2027, each subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the Issuer's 2027 annual meeting of the stockholders (or the date immediately prior to such annual meeting if the Reporting Person's service as a director ends at such annual meeting) or (ii) on May 21, 2027, each subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.

Workday, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	10,547	Reported balance After 2026-06-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 2,366 · Balance 10,547 F1: Includes 2,694 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 2,336 RSUs from an original grant with a grant date of 6/16/2026 which will vest 100% on 5/5/2027. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 2,694 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 2,336 RSUs from an original grant with a grant date of 6/16/2026 which will vest 100% on 5/5/2027. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forma Therapeutics Holdings, Inc.

Report date October 14, 2022 · Filed October 14, 2022

Section 16 reporting ended · disclosed 2022-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-14 transaction · row 1 1 source row Row 1 · 2022-10-14 · Other · Disposed 7,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.00	Direct	Reported balance After 2022-10-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-14 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.35	Direct	Reported balance After 2022-10-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-14 · Disposition to issuer · Disposed 8,375 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.12	Direct	Reported balance After 2022-10-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-14 · Disposition to issuer · Disposed 6,750 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest.

F2: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jun 18, 2026 20:52 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	2,366	$0.00	$0.00	Disclosure SEC source: 0001802241-26-000006 · wk-form4_1781815946.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,547 F1 · balance_after: Includes 2,694 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 2,336 RSUs from an original grant with a grant date of 6/16/2026 which will vest 100% on 5/5/2027. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
May 21, 2026 Filed May 27, 2026 01:45 UTC	Tempus AI, Inc. TEM · Entity 1545	GrantClass A Common Stock	5,913	$0.00	$0.00	Disclosure SEC source: 0001802241-26-000004 · form4-05262026_090508.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,749 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the Issuer's 2027 annual meeting of the stockholders (or the date immediately prior to such annual meeting if the Reporting Person's service as a director ends at such annual meeting) or (ii) on May 21, 2027, each subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document
May 20, 2026 Filed May 21, 2026 20:30 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,660	$0.00	$0.00	Disclosure SEC source: 0001145197-26-000123 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,818 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. The Reporting Person has elected to defer settlement of these RSUs pursuant to the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the termination of the Reporting Person's service as a Director. Read SEC document
January 02, 2026 Filed Jan 5, 2026 19:19 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	766	$0.00	$0.00	Disclosure SEC source: 0001802241-26-000002 · form4.xml · derivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,174 Underlying: Humana Common · 766 shares Expires not disclosed F1 · security: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · derivative.exercise_price: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · derivative.exercise_date: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · derivative.expiration_date: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · balance_after: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. Read SEC document
December 31, 2025 Filed Jan 5, 2026 19:19 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	35	$258.87	$9,060.36	Disclosure SEC source: 0001802241-26-000002 · form4.xml · derivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73 Underlying: Humana Common · 35 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document
December 15, 2025 Filed Dec 16, 2025 21:04 UTC	INSULET CORP PODD · Entity 3516	SaleCommon Stock	1,851	$293.09	$542,509.59	Disclosure SEC source: 0001145197-25-000074 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,158 Read SEC document
December 05, 2025 Filed Dec 9, 2025 21:15 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	3,675	$77.23	$283,820.25	Disclosure SEC source: 0001802241-25-000004 · form4-12092025_041201.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,836 Read SEC document
June 04, 2025 Filed Jun 5, 2025 20:54 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	1,336	$0.00	$0.00	Disclosure SEC source: 0001327811-25-000120 · wk-form4_1749156710.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,181 F1 · balance_after: Includes 2,976 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 1,336 RSUs from an original grant with a grant date of 6/4/2025 which will vest 100% on 5/5/2026. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
May 22, 2025 Filed May 27, 2025 20:05 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	778	$0.00	$0.00	Disclosure SEC source: 0001127602-25-015644 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,009 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2026. The Reporting Person has elected to defer settlement of these RSUs pursuant to the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the termination of the Reporting Person's service as a Director. Read SEC document
May 20, 2025 Filed May 23, 2025 00:00 UTC	Tempus AI, Inc. TEM · Entity 1545	GrantClass A Comnmon Stock	1,997	$0.00	$0.00	Disclosure SEC source: 0001415889-25-014308 · form4-05222025_080522.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,511 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the Issuer's 2026 annual meeting of the stockholders (or the date immediately prior to such annual meeting if the Reporting Person's service as a director ends at such annual meeting) or (ii) on May 20, 2026, each subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document
March 31, 2025 Filed Apr 2, 2025 22:13 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	3,000	$45.54	$136,620.00	Disclosure SEC source: 0001415889-25-009766 · form4-04022025_100400.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,514 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024. Read SEC document
March 25, 2025 Filed Mar 26, 2025 20:22 UTC	INSULET CORP PODD · Entity 3516	SaleCommon Stock	1,825	$275.00	$501,875.00	Disclosure SEC source: 0001127602-25-010481 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,231 F1 · shares: The transaction reported in this Form 4 was effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document
March 17, 2025 Filed Mar 19, 2025 22:30 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	1,003	$50.62	$50,771.86	Disclosure SEC source: 0001415889-25-008653 · form4-03192025_060303.xml · nonDerivative · entry 5 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,514 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.43 to $50.81 inclusive. Read SEC document
March 17, 2025 Filed Mar 19, 2025 22:30 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	3,188	$49.99	$159,368.12	Disclosure SEC source: 0001415889-25-008653 · form4-03192025_060303.xml · nonDerivative · entry 4 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,517 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.43 to $50.42 inclusive. Read SEC document
March 17, 2025 Filed Mar 19, 2025 22:30 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	1,100	$48.79	$53,669.00	Disclosure SEC source: 0001415889-25-008653 · form4-03192025_060303.xml · nonDerivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,705 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.38 to $49.22 inclusive. Read SEC document
March 17, 2025 Filed Mar 19, 2025 22:30 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	2,059	$47.99	$98,811.41	Disclosure SEC source: 0001415889-25-008653 · form4-03192025_060303.xml · nonDerivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,805 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.38 to $48.33 inclusive. Read SEC document
March 17, 2025 Filed Mar 19, 2025 22:30 UTC	Tempus AI, Inc. TEM · Entity 1545	SaleClass A Common Stock	1,650	$46.69	$77,038.50	Disclosure SEC source: 0001415889-25-008653 · form4-03192025_060303.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,864 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.18 to $47.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6). Read SEC document
January 02, 2025 Filed Jan 3, 2025 21:46 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	783	$0.00	$0.00	Disclosure SEC source: 0001062993-25-000210 · form4.xml · derivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,408 Underlying: Humana Common · 783 shares Expires not disclosed F1 · security: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · derivative.exercise_price: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · derivative.exercise_date: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · derivative.expiration_date: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. F1 · balance_after: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a I-for-I basis, exempt pursuant to Rule 16(b)-3(d)(I). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule I 6b-3(d)(I )&(3) under the Company's 2019 Amended & Restated Plan. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	200	$257.50	$51,499.00	Disclosure SEC source: 0001327811-25-000002 · wk-form4_1736198729.xml · nonDerivative · entry 6 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $257.14 to $258.1399, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	200	$256.23	$51,245.00	Disclosure SEC source: 0001327811-25-000002 · wk-form4_1736198729.xml · nonDerivative · entry 5 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,045 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $255.79 to $256.7899, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	100	$254.63	$25,463.00	Disclosure SEC source: 0001327811-25-000002 · wk-form4_1736198729.xml · nonDerivative · entry 4 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,245 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $254.63 to $255.6299, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	200	$253.12	$50,624.00	Disclosure SEC source: 0001327811-25-000002 · wk-form4_1736198729.xml · nonDerivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $252.95 to $253.9499, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	629	$252.10	$158,572.79	Disclosure SEC source: 0001327811-25-000002 · wk-form4_1736198729.xml · nonDerivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,545 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $251.80 to $252.7999, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:25 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	500	$251.00	$125,500.00	Disclosure SEC source: 0001327811-25-000002 · wk-form4_1736198729.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,174 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $250.79 to $251.7899, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:46 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	23	$254.93	$5,863.39	Disclosure SEC source: 0001062993-25-000210 · form4.xml · derivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38 Underlying: Humana Common · 23 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document
October 11, 2024 Filed Oct 15, 2024 20:12 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	200	$243.91	$48,782.00	Disclosure SEC source: 0001327811-24-000218 · wk-form4_1729023166.xml · nonDerivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,674 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $243.56 to $244.5599, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
October 11, 2024 Filed Oct 15, 2024 20:12 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	600	$242.15	$145,288.98	Disclosure SEC source: 0001327811-24-000218 · wk-form4_1729023166.xml · nonDerivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,874 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $241.86 to $242.8599, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
October 11, 2024 Filed Oct 15, 2024 20:12 UTC	Workday, Inc. WDAY · Entity 1785	SaleClass A Common Stock	1,028	$241.28	$248,034.81	Disclosure SEC source: 0001327811-24-000218 · wk-form4_1729023166.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,474 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person dated July 12, 2024. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $240.78 to $241.7799, inclusive. The Reporting Person undertakes to provide to Workday, Inc., any security holder of Workday, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3 · balance_after: Includes 3,851 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement. All grants are subject to the Reporting Person's continued service with the Issuer on the applicable vesting dates. Read SEC document
June 18, 2024 Filed Jun 21, 2024 20:26 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	1,555	$0.00	$0.00	Disclosure SEC source: 0001327811-24-000119 · wk-form4_1719001564.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,502 F1 · balance_after: Includes 4,507 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 1,555 RSUs from an original grant with a grant date of 6/18/2024 which will vest 100% on 5/5/2025. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
June 13, 2024 Filed Jun 18, 2024 01:45 UTC	Tempus AI, Inc. TEM · Entity 1545	GrantClass A Common Stock	38,514	$0.00	$0.00	Disclosure SEC source: 0001415889-24-017307 · form4-06172024_090614.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,514 F1 · shares: Consists of previously granted restricted stock units ("RSUs") for which the liquidity event-based condition was satisfied upon the effectiveness of the registration statement on Form S-1 filed by the Issuer in connection with the Issuer's initial public offering, as well as, a grant of RSUs made in connection with the Issuer's Non-Employee Director Compensation Policy. Certain of the RSUs remain subject to service-based vesting conditions, as follows: (i) 7,500 RSUs vest in six equal quarterly installments commencing on July 1, 2024 and (ii) 13,514 RSUs vest in 20 substantially equal quarterly installments commencing on September 13, 2024. Read SEC document
May 22, 2024 Filed May 23, 2024 21:06 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,380	$0.00	$0.00	Disclosure SEC source: 0001127602-24-016456 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,056 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2025. The Reporting Person has elected to defer settlement of these RSUs pursuant to the Insulet Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the termination of the Reporting Person's service as a Director. Read SEC document
January 02, 2024 Filed Jan 3, 2024 21:46 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	430	$0.00	$0.00	Disclosure SEC source: 0001062993-24-000218 · form4.xml · derivative · entry 4 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430 Underlying: Humana Common · 430 shares Expires not disclosed F3 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/24. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/24. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/24. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/24. Read SEC document
December 31, 2023 Filed Jan 3, 2024 21:46 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	9	$456.91	$4,112.22	Disclosure SEC source: 0001062993-24-000218 · form4.xml · derivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15 Underlying: Humana Common · 9 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document
October 05, 2023 Filed Nov 16, 2023 00:10 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	107	$0.00	$0.00	Disclosure SEC source: 0001327811-23-000193 · wk-form4_1700093433.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,947 F1 · balance_after: Includes 5,230 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 107 RSUs from an original grant with a grant date of 10/5/2023 which will vest 100% on 5/5/2024. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
June 22, 2023 Filed Jun 26, 2023 22:23 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	1,515	$0.00	$0.00	Disclosure SEC source: 0001327811-23-000120 · wf-form4_168781819882512.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,840 F1 · balance_after: Includes 6,763 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including 1,515 RSUs from an original grant with a grant date of 6/22/2023 which will vest 100% on 5/5/2024. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
May 23, 2023 Filed May 24, 2023 20:06 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	843	$0.00	$0.00	Disclosure SEC source: 0001127602-23-016711 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,676 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. Read SEC document
January 03, 2023 Filed Jan 4, 2023 19:14 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	380	$0.00	$0.00	Disclosure SEC source: 0001062993-23-000155 · form4.xml · derivative · entry 4 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380 Underlying: Humana Common · 380 shares Expires not disclosed F3 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/23. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/23. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/23. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/23. Read SEC document
December 31, 2022 Filed Jan 4, 2023 19:14 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	4	$510.30	$2,041.18	Disclosure SEC source: 0001062993-23-000155 · form4.xml · derivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6 Underlying: Humana Common · 4 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document
October 14, 2022 Filed Oct 14, 2022 16:07 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	Disposition to issuerStock Option (Right to Buy) · Derivative	6,750	Not disclosed Strike: $6.12	Not disclosed	Disclosure SEC source: 0000899243-22-033657 · doc4.xml · derivative · entry 4 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,750 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document
October 14, 2022 Filed Oct 14, 2022 16:07 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	Disposition to issuerStock Option (Right to Buy) · Derivative	8,375	Not disclosed Strike: $25.35	Not disclosed	Disclosure SEC source: 0000899243-22-033657 · doc4.xml · derivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,375 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document
October 14, 2022 Filed Oct 14, 2022 16:07 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $35.00	Not disclosed	Disclosure SEC source: 0000899243-22-033657 · doc4.xml · derivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable. Read SEC document
October 14, 2022 Filed Oct 14, 2022 16:07 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	OtherCommon Stock	7,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033657 · doc4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the "Issuer"), Novo Nordisk A/S (the "Parent"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of October 14, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the "Merger Consideration"), subject to withholding of applicable taxes and without interest. F2 · kind: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · shares: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. F2 · price: Consists of restricted stock units ("RSUs"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document
July 15, 2022 Filed Jul 19, 2022 20:34 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	5,248	$0.00	$0.00	Disclosure SEC source: 0001327811-22-000144 · wf-form4_165826282789523.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,325 F1 · balance_after: Includes 7,325 restricted stock units ("RSUs"), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, including an original grant consisting of 5,248 RSUs with a grant date of 7/15/2022, which will vest as to 25% of the underlying shares on the one-year anniversary of grant and then quarterly thereafter. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:26 UTC	Workday, Inc. WDAY · Entity 1785	GrantClass A Common Stock	2,077	$0.00	$0.00	Disclosure SEC source: 0001327811-22-000126 · wf-form4_165610236213355.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,077 F1 · balance_after: Includes 2,077 restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of Class A Common Stock upon settlement, from an original grant consisting of 2,077 RSUs with a grant date of 6/22/2022, which will vest 100% on 5/15/2023. All grants are subject to the Reporting Person's continued service with Workday on the applicable vesting date. Read SEC document
June 08, 2022 Filed Jun 9, 2022 17:37 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantStock Option (Right to Buy) · Derivative	6,750	$0.00 Strike: $6.12	$0.00	Disclosure SEC source: 0000899243-22-021669 · doc4.xml · derivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 6,750 shares Expires 2032-06-07 F2 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 8, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 08, 2022 Filed Jun 9, 2022 17:37 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0000899243-22-021669 · doc4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,250 F1 · shares: These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock. Read SEC document
May 24, 2022 Filed May 26, 2022 20:07 UTC	INSULET CORP PODD · Entity 3516	GrantCommon Stock	1,009	$0.00	$0.00	Disclosure SEC source: 0001127602-22-015762 · form4.xml · nonDerivative · entry 1 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,833 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis. Read SEC document
January 03, 2022 Filed Jan 4, 2022 14:34 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	412	$0.00	$0.00	Disclosure SEC source: 0001062993-22-000111 · form4.xml · derivative · entry 4 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412 Underlying: Humana Common · 412 shares Expires not disclosed F3 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/22. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/22. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/22. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under Company's 2019 Amended & Restated Plan.100% of the award is vesting on 12/31/22. Read SEC document
December 31, 2021 Filed Jan 4, 2022 14:34 UTC	HUMANA INC HUM · Entity 1429	GrantRestricted Stock Units · Derivative	2	$465.85	$931.70	Disclosure SEC source: 0001062993-22-000111 · form4.xml · derivative · entry 3 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Humana Common · 2 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document
June 17, 2021 Filed Jun 21, 2021 19:06 UTC	Forma Therapeutics Holdings, Inc. FMTX · Entity 123059	GrantStock Option (Right to Buy) · Derivative	8,375	$0.00 Strike: $25.35	$0.00	Disclosure SEC source: 0000899243-21-025096 · doc4.xml · derivative · entry 2 Frederick Wayne A.I. · CIK 0001802241 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,375 Underlying: Common Stock · 8,375 shares Expires 2031-06-16 F2 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 17, 2022 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.